Last Updated on May 3, 2025 by The Health Master
Delhi High Court
In a significant move prioritizing child safety, the Delhi High Court has issued a firm directive to pharmaceutical companies.
The court has mandated that these companies must immediately disseminate clear advisories to doctors, chemists, and retailers explicitly stating that fixed-dose combination (FDC) cough syrups are strictly prohibited for administration to children below the age of four.
This decisive action comes in response to a petition filed by prominent drug manufacturers Glenmark and Zuventus Healthcare, who contested the central government’s notification issued on April 15th.
This government order had placed a ban on specific cough syrup brands for children under the age of four, citing critical safety concerns for this vulnerable age group.
Court Addresses Retrospective Application and Emphasizes Future Compliance
While a bench presided over by Chief Justice DK Upadhaya acknowledged the drug manufacturers’ contention that the government order should not be applied retroactively, the court unequivocally stated that the pharmaceutical firms must adhere meticulously to the government’s notification for all drug batches manufactured on or after April 15th.
To ensure widespread awareness and compliance, the court has instructed the companies to prominently include a specific warning on all packaging labels and promotional materials.
This crucial warning must clearly read, “Fixed combination not to be used for children below four years.”
This step aims to provide immediate and visible guidance to parents and healthcare professionals alike, reinforcing the potential health risks for infants and toddlers associated with these medications.
Mandatory Public Notices for Enhanced Awareness
Going beyond labeling requirements, the Delhi High Court has also directed the manufacturers to publish clear and conspicuous notices in two national newspapers with extensive nationwide circulation—one in English and one in Hindi.
These notices are specifically mandated to be designed in a manner that effectively captures the attention of the general public.
This proactive measure underscores the urgency and importance of the information, ensuring that parents and caregivers across the nation are informed about the potential dangers of cough medicine for toddlers.
The court explicitly clarified that these essential public notices should not be construed as advertisements and will not be considered a breach of drug license conditions, highlighting the paramount importance of public health communication over commercial considerations.
Government’s Stance Rooted in Safety Evaluations
The central government’s directive issued in April stems from thorough safety evaluations conducted by the drug regulator.
These evaluations raised significant concerns regarding the use of certain FDC cough syrups in young children, ultimately leading to the ban.
Consequently, manufacturers have also been instructed to incorporate explicit warnings on drug labels and package inserts for all future production.
This comprehensive approach, now reinforced by the Delhi High Court’s order, signifies a strong commitment to safeguarding the health and well-being of young children by mitigating potential risks associated with these medications.
This development is crucial information for parents seeking safe children’s cold remedies and understanding the limitations of over-the-counter options.
Q. What are fixed-dose combination (FDC) cough syrups?
A. FDC cough syrups contain a combination of two or more active pharmaceutical ingredients intended to treat various cold and cough symptoms simultaneously.
Q. Why are these cough syrups now restricted for children under four?
A. Safety evaluations by the drug regulator have raised concerns about the potential risks and adverse effects of these combinations in very young children.
Q. What should parents do if their child under four has a cough?
A. Parents should consult a pediatrician for appropriate diagnosis and treatment options suitable for their child’s age and specific condition. Avoid self-medicating with over-the-counter cough syrups without professional medical advice.
Q. Will this affect cough syrups for older children and adults?
A. The current directive specifically targets the use of FDC cough syrups in children below the age of four. Regulations for older age groups may differ.
Q. Where will these public notices be published?
A. The notices will appear in one leading national English newspaper and one leading national Hindi newspaper to ensure broad reach across the country.
Q. When do these new rules come into effect?
A . Pharmaceutical companies must comply with the government’s notification for all drugs manufactured after April 15th and issue advisories immediately.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
Disclaimer: The information we have provided is for general knowledge and for informational purpose only and it cannot be treated as medical advice. Always consult your doctor for any health issues and / or for the treatment of the same. The Health Master does not claim responsibility for this information.
DCA Telangana seizes huge quantity of Cough Syrup
Drug Bust in Patna: Crackdown on Illegal Cough Syrups Trade
ICMR recommends ban on Nimesulide for these age groups
Drug recall: Dr Reddy’s and Lupin recall drugs due to these reasons
Key Notes on Revised Schedule M: API Part-4
FDA Haryana targets illegal sale of MTP Kits
65 Major Drug Seizures by DCA Telangana in March
FSSAI: Food Labelling and Display – Chapter-17
Gap analysis for Revised Schedule M
USFDA issues EIR for Emcure Pharma for Pune facility
USFDA approval granted for generic Hypertension drug
Govt restricts Cold Medicine for Children Under Four
